Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05187338

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

Triplex CTLA4/PD1/PDL1 Checkpoint Inhibitors Combination Therapy for Advanced Solid Tumors

Sponsor: Second Affiliated Hospital of Guangzhou Medical University

Conditions Breast Cancer Cervical Cancer Colorectal Cancer Esophageal Cancer Gastric Cancer Head and Neck Cancer Liver Cancer Lung Cancer Ovary Cancer Pancreas Cancer Sarcoma

Interventions ipilimumab +pembrolizumab +durvalumab

Updated 4 times since 2022 Last updated: Jun 23, 2024 Started: Nov 1, 2021 Primary completion: Oct 30, 2029 Completion: Oct 30, 2035

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05187338, this PHASE1/PHASE2 trial focuses on Breast Cancer and Cervical Cancer and remains actively recruiting participants. Sponsored by Second Affiliated Hospital of Guangzhou Medical University, it has been updated 4 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Mar 2023 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Feb 2022 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Second Affiliated Hospital of Guangzhou Medical University

Data source: Second Affiliated Hospital of Guangzhou Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China